Compare Accenture plc (ACN) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Accenture plc vs Nuwellis Inc — how do they compare? Accenture plc trades at $179.06 (market cap $109.08B), while Nuwellis Inc trades at $1.49 (market cap $522.76K). The key difference: Accenture plc is far larger — about 208661.7× Nuwellis Inc's market cap, and Accenture plc pays a 3.66% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| ACN | NUWE | |
|---|---|---|
Market Cap | $109.08B | $522.76K |
Sector | Technology | Technology |
52-Week High | $288.54 | $220.50 |
52-Week Low | $124.41 | $1.42 |
Enterprise Value | $107.30B | -$1.29M |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $179.82, up 2.33% in the last session, with a bullish technical outlook and strong fundamental performance. The stock exhibits robust revenue growth, with 2025 revenue reaching $69.67 billion and net income of $7.68 billion, supported by consistent earnings beats. Recent partnerships with TEPCO Solution Advance and AlphaSense highlight strategic AI initiatives, enhancing its consulting and digital transformation services.
The investment outlook is positive, driven by solid financials, a consensus price target of $189.77, and low debt. Risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is strongly bullish with 66% buy ratings, indicating confidence in continued growth and shareholder value creation.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
